Drugs / PanChol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07107516 | Oct 2025 → Jan 2026 overdue | vaccinia | Centre for Infectious Disease Research in Zambia | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05657782 | Dec 2022 → Dec 2024 | cholera, poisoning | Brigham and Women's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Panchol | “Panchol is a novel live attenuated oral cholera vaccine.” NCT07107516 ↗ |
| Modality | Vaccine | “PanChol is a new second generation live-attenuated oral cholera vaccine (OCV)” NCT05657782 ↗ |
| Route | Oral | “PanChol is a single-dose, live-attenuated, oral cholera vaccine derived from a current seventh pandemic Vibrio cholerae O1 strain.” PMID 41519137 ↗ Jan 2026 |